|
- In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Here we discuss the most recent progress of in vivo delivery of CRISPR-Cas9 systems, highlight innovative viral and non-viral delivery technologies, emphasize outstanding delivery challenges, and provide the most updated perspectives
- Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer . . . - AAAS
In this study, we present a strategy using cryo-shocked lung tumor cells as a CRISPR-Cas9 delivery system for cyclin-dependent kinase 4 (CDK4) gene editing, which initiates synthetic lethal in KRAS-mutant non–small cell lung cancer (NSCLC)
- Nanotechnology-Based Delivery of CRISPR Cas9 for Cancer . . . - MDPI
A critical aspect of in vivo CRISPR Cas9 application is to achieve effective localization at the tumor site while minimizing off-target effects Nanocarriers can be engineered to overcome biological barriers, thereby augmenting tumor-specific delivery and facilitating intracellular uptake
- Enhanced CRISPR-Cas9 RNA system delivery using cell . . . - PubMed
This study introduces a promising new Peptide-Based Nanoparticles for delivering CRISPR-Cas9 system in its RNA form applicable in both in vitro and in vivo models
- Exosome-mediated delivery of CRISPR-Cas9: A . . . - ScienceDirect
The following review discusses the current progress in using exosomes to deliver CRISPR-Cas9 components, the approaches to load the CRISPR components into exosomes, and the modification of exosomes to increase stability and tumor-targeted delivery
- Development of CRISPR Cas Delivery Systems for In Vivo Precision Genome . . .
In this Account, we summarize our recent achievements in developing different types of materials that can efficiently deliver the plasmid DNA encoding Cas9 protein and single-guide RNA (sgRNA), or Cas9 RNP into cells to highlight the design considerations of carriers for safe and efficient delivery in vitro and in vivo
- Delivery systems of CRISPR Cas9-based cancer gene therapy
In this review, we want to give a general overview to the recent advancements in the delivery systems of the CRISPR Cas9 machinery in cancer therapy Cancer, unlike other genetic diseases such as Duchenne Muscle Dystrophy, HPV, HBV, Cystic Fibrosis, etc , relies on several genetic mutations
- Delivery Approaches for CRISPR Cas9 Therapeutics In Vivo: Advances and . . .
In this topical review, we highlight recent advances to in vivo delivery of the CRISPR Cas9 system using various packaging formats, including viral, mRNA, plasmid, and protein-based approaches We also discuss some of the barriers which have yet to be overcome for successful translation of this technology
|
|
|